9-Nitrocamptothecin polymeric nanoparticles: Cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats

Anti-Cancer Drugs

Volumn 19, Issue 8, 2008, Pages 805-811

  Dadashzadeh, Simin ^a,b   Derakhshandeh, Katayoun ^a,c   Shirazi, Farshad Hoseini ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

9 nitrocamptothecin; Cytotoxicity; Nanoparticles; Pharmacokinetics; Poly (DL lactic glycolic acid)

Indexed keywords

NANOPARTICLE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; RUBITECAN; 9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; LACTONE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; HUMAN; HUMAN CELL; MALE; MEAN RESIDENCE TIME; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; WISTAR RAT; ANIMAL; CELL SURVIVAL; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INJECTIONS, INTRAVENOUS; LACTONES; MALE; NANOPARTICLES; RATS; RATS, WISTAR; TETRAZOLIUM SALTS; THIAZOLES;

EID: 53749104543     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283099e5c     Document Type: Article

References (40)

1. Kreuter J. Nanoparticle-based drug delivery systems. J Control Rel 1991; 16:169-176.
2. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 2002; 54:631-651.
3. Bannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Del Rev 2004; 56:1649-1659.
4. Zamboni WC. Liposomal, nanoparticle and conjugated formulations of anticancer agents. Clin Cancer Res 2005; 11:8230-8234.
5. Couvreur P, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci 1982; 71:790-792.
6. Kim SY, Lee YM. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(ε-caprolactone) as novel anticancer drug carriers. Biomaterials 2001; 22:1697-1704.
7. Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M, Speiser P. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci 1980; 69:199-202.
8. Baban D, Seymour LW. Control of tumor vascular permeability. Adv Drug Del Rev 1998; 34:109-119.
9. Yuan F, Dellian D, Fukumura M, Leuning DD, Berk VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cut off size. Cancer Res 1995; 55:3752-3756.
10. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000; 65:271-284.
11. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer-mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Cancer Sci 2000; 11:265-283.
12. Giovanella BC, Stehlin JS, Hinz HR, Kozielsk AJ, Harris NJ, Vardeman DM. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(s)-camptothecin (Rubitecan). Int J Oncol 2002; 20:81-88.
13. Stehlin JS, Giovanella BC, Natelson EA, De Ipolyi PD, Coli D, Davis B. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14:821-831.
14. Hung CL, Doniger J, Palini A, Snyder SW, Radonovich MF, Brady JN, et al. 9-Nitrocamptothecin inhibits HIV-1 replication in human periperal blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. J Med Virol 2001; 64:238-244.
15. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81:676-684.
16. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994; 37:40-46.
17. Chen J, Ping QN, Guo XZ, Song MM. Effect of phospholilid composition on characterization of liposomes containing 9-nitrocamtothecin. Drug Dev Ind Pharm 2006; 32:719-726.
18. Chow DSL, Gong L, Wolfe MD, Giovanella BC. Modified lactone/ carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin. Ann N Y Acad Sci 2000; 922:151-163.
19. Vali AM, Toliyat T, Shafaghi B, Dadashzadeh S. Preparation, optimization and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm 2008; 34:10-23.
20. Gerrits CJH, Jong MJA, Schellens JHM, Stoter G,Verweij J. Topoisomerase I inhibitors: the relevance of prolonged expose for present clinical development. Br J Cancer 1997; 76:952-962.
21. Hochster H, Liebes L, Speyer J. Phase I trial of low-dose continuous TPT infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncology 1994; 12:553-559.
22. Gupta E, Vyas V, Ahmed F, Sinko P, Cook T, Rubin E. Pharmacokinetics of orally administered camptothecins. Ann N Y Acad Sci 2000; 922:195-204.
23. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water insoluble topoisomerase I inhibitor. Anticancer Drugs 1998; 9:36-44.
24. Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP. Phase I and pharmacologic study of intermittently administered 9-nitro- camptothecin in patients with advanced solid tumors. Clin Cancer Res 2004; 10:5058-5064.
25. Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm 2007; 66:34-41.
26. Shenderova A, Burke TG, Schwendeman SP. The acidic microclimate in poly (lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 1999; 16:241-248.
27. Shenderova A, Burke TG, Schwendeman SP. Stabilization of 10-hydroxy camptothecin in poly (lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 1997; 14:1406-1414.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
29. Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JHM. Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Lab Anim 2003; 37:181-187.
30. Derakhshandeh K, Dadashzadeh S. Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma. J Chromatogr B 2005; 818:199-204.
31. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 4th ed. Connecticut: Appleton & Lange; 1999. pp. 67-98.
32. Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Rel 2003; 91:167-172.
33. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Rel 2001; 70:63-70.
34. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 1999; 59:299-307.
35. Koziara JM, Lockman RP, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Rel 2004; 99:259-269.
36. Sha X, Fang X. Transport characteristics of 9-nitrocamptothecinin the human intestinal cell line Caco-2 and everted gut sacs. Int J Pharm 2004; 272:161-171.
37. Lorence A, Nessler CL. Camptothecin, over four decades of surprising findings. Phytochemistry 2004; 65:2735-2749.
38. Chen J, Ping Q, Guo J, Chu X, Song M. Pharmacokinetics of lactone, carboxylate and total 9-nitrocamtothecin with different doses and administration routes in rats. Biopharm Drug Dispos 2006; 27:53-59.
39. Onishi H, Machida Y, Machida Y. Antitumor properties of irinotecan containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-blockpoly(ethylene glycol). Biol Pharm Bull 2003; 26:116-119.
40. Reddy HL, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly (butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap 2004; 148:161-166.